United Kingdom National Virology Consortium News Today : Breaking News, Live Updates & Top Stories | Vimarsana

An essential line of defence in a global living-with-COVID-19 policy is formed by effective therapeutic strategies for vulnerable patients,1 many of whom are excluded from treatment with nirmatrelvir–ritonavir (sold as Paxlovid, Pfizer) by virtue of their comorbidities or interacting medications. Preliminary data suggest that monoclonal antibodies (mAbs) is highly effective for these groups,2 and WHO, in its Therapeutics and COVID-19: Living Guideline,3 has previously conditionally recommended the use of sotrovimab (sold as Xevudy, Vir Biotechnology and GlaxoSmithKline) or casirivimab–imdevimab (sold as Ronapreve, Regeneron) for people at high risk of hospitalisation.

United kingdomCity ofUniversity college londonUnited kingdom national health serviceUnited kingdom national virology consortiumElsevier ltdUniversity college london hospitalsInternational unitsKings cross health research authorityInternational standardSarah canon research instituteFrancis crick instituteLondon camdenUniversity collegeBicycle therapeuticsApogen biotech